4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 5.2% – Time to Buy?

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) rose 5.2% during trading on Tuesday . The stock traded as high as $10.78 and last traded at $10.9650. Approximately 101,193 shares were traded during mid-day trading, a decline of 87% from the average session volume of 767,988 shares. The stock had previously closed at $10.42.

Wall Street Analysts Forecast Growth

FDMT has been the topic of a number of recent research reports. Chardan Capital restated a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. The Goldman Sachs Group set a $33.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, May 8th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

4D Molecular Therapeutics Stock Performance

The stock’s 50-day simple moving average is $9.44 and its two-hundred day simple moving average is $9.12. The stock has a market cap of $573.30 million, a price-to-earnings ratio of -4.26 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. As a group, research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current year.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its position in 4D Molecular Therapeutics by 17.0% in the 1st quarter. Bank of America Corp DE now owns 974,173 shares of the company’s stock worth $9,070,000 after buying an additional 141,582 shares during the period. Janus Henderson Group PLC boosted its position in shares of 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after acquiring an additional 611,276 shares during the period. Exome Asset Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter worth $1,216,000. Renaissance Technologies LLC grew its stake in shares of 4D Molecular Therapeutics by 12.7% in the first quarter. Renaissance Technologies LLC now owns 578,265 shares of the company’s stock worth $5,384,000 after acquiring an additional 65,365 shares during the last quarter. Finally, Sei Investments Co. grew its stake in shares of 4D Molecular Therapeutics by 8.9% in the first quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock worth $120,000 after acquiring an additional 1,050 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.